MedTrace Logo

Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively

NCT02605538 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-03-18

No results posted yet for this study

Summary

CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization has been complete.

Conditions

Interventions

BIOLOGICAL

Vaccination with vaccine against hepatitis A and B

Vaccination against hepatitis A and B

Sponsors & Collaborators

Principal Investigators

  • Ferenc Karpati, MD, PhD · Stockholm CF Center, Karolinska University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2023-12-31
Completion
2025-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02605538 on ClinicalTrials.gov